Satellos Bioscience (MSLE) Assets (2023 - 2026)

Satellos Bioscience (MSLE) posted quarterly Assets of $75.2 million for Q1 2026, up 135.9% quarter-over-quarter from $31.9 million in Q4 2025.

Satellos Bioscience (MSLE) Assets (2023 - 2026) Analysis & Trends

Satellos Bioscience (MSLE) has reported Assets for 4 consecutive years, with $75.2 million the latest figure, recorded in Q1 2026.

In Q1 2026, Assets changed N/A year-over-year to $75.2 million; the TTM figure through Mar 2026 stood at $75.2 million (changed N/A YoY), while the FY2025 annual figure was $31.9 million, down 37.16% from the prior year.
Assets advanced to $75.2 million in Q1 2026 per MSLE's latest filing, from $31.9 million in the prior quarter.
Across five years, Assets topped out at $75.2 million in Q1 2026 and bottomed at $31.9 million in Q4 2025.
Historically, Assets has averaged $48.0 million across 4 years, with a median of $42.4 million in 2024.
Annual changes were most pronounced in 2024 — Assets jumped 60.64% — and 2025, when it slumped 38.99%.
Satellos Bioscience's Assets stood at $32.5 million in 2023, then soared by 60.64% to $52.3 million in 2024, then slumped by 38.99% to $31.9 million in 2025, then soared by 135.9% to $75.2 million in 2026.
Business Quant data shows MSLE's Assets at $75.2 million in Q1 2026, $31.9 million in Q4 2025, and $52.3 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	27.42 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	41.73 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	10.03 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	10.96 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	9.18 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	5.56 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	2.10 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.82 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	25.60 Bn
10	Satellos Bioscience	208.31 Mn	208.31 Mn	-	65.77 Mn

Download Data